Photo by marceloleal80 from unsplash
357 COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA P. Panayiotidis | A. Kellner | G.A. Follows | L. Mollica | A. Nagler | M. Özcan |… Click to show full abstract
357 COPANLISIB TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA P. Panayiotidis | A. Kellner | G.A. Follows | L. Mollica | A. Nagler | M. Özcan | A. Santoro | F. Hiemeyer | L. Liu | J. Garcia-Vargas | B.H. Childs | P.L. Zinzani | M. Dreyling School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Hematology, Kaposi Mór Teaching Hospital, Kaposvár, Hungary; Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; Clinical Research in Hematology and Clinical Oncology, Maisonneuve-Rosemont Hospital Research Centre, Montréal, Quebec, Canada; Chaim Sheba Medical Center, Tel Aviv University, Tel HaShomer, Israel; Hematology, Ankara University, Ankara, Turkey; Cancer Center, Humanitas Clinical and Research Center, Rozzano, Italy; Pharmaceutical Division, Bayer AG, Berlin, Germany; Oncology, Bayer HealthCare Pharmaceuticals, Inc., Whippany, United States; Institute of Hematology "Seràgnoli", University of Bologna, Bologna, Italy; Department of Medicine III, University Hospital (LMU), Munich, Germany
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!